We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 38,838 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/4/2020 07:58 | Lauders - thanks for posting the seekingalpha link. It spreads the news to our investing friends across the pond. The same people who increased the Gilead stock price by $11 billion. I suspect a few may buy here. The article was published last night US time. | pdt | |
03/4/2020 07:47 | Respect Nobby, Now this is interesting: Bloke in the states taking about Synairgen working with the FDA? And ofcourse...... Sandy Aitken Reserch Nurse on Twitter We now have randomised 6 patients to the SG016 study. This is amazing in 4 days of starting. And Went into work early today. Handed over to my colleague Pedro Rorigues. Synairgen study doing well I think. However, I am now at home trying to rest until tomorrow. I will keep everyone update with recruitment to study. | likya123 | |
03/4/2020 07:44 | Look here KoP202, I am going to swear at the next person who spoils my breakfast by mentioning b----y IMM....! | mostro | |
03/4/2020 07:41 | Lauders it's not quite a bust is it?There are other viral infections which synairgen can treatCertainly the market will wipe out the share price to single figures if it doesn't prove to be an effective treatment for covidBut at least it's not a one trick pony...like IMM | kop202 | |
03/4/2020 02:48 | Summary Clearly, there are winners as well as losers in any stock market, even the current one. Those who might have a cure or treatment for COVID-19 are the obvious winners, as with Synairgen. The stock has already risen substantially, but if the treatment actually works, there's a lot more to go. Goes into the company detail and risks/benefits of an investment, so is a useful read. This part at the end is worth sharing here: The downside here is that it's a bust in that it doesn't treat the infection. The upside is that it might - and also that near all of the other barriers to completion have been swept away. The company is financed, and the regulatory apparatus is primed to be helpful to it. The investor view This is obviously significantly speculative, and none of us can possibly know how it's going to perform in those trials. Yet, given all of the other issues, it's worth a speculative punt. A small amount from the tail end of the portfolio, certainly nothing more than a percent or so of total holdings. I concur with the Sunday Times - Synairgen stock is a Buy in modest quantities given the risks. | lauders | |
03/4/2020 00:41 | Excellent feedback, agreed. | jev1 | |
02/4/2020 23:31 | Post of the day was from rafboy IMHO. I paste the link below which he highlighted. The significance of recruiting 6 patients in 4 days is enormous.... | nobbygnome | |
02/4/2020 21:58 | Understood jev- thanks | makendon | |
02/4/2020 21:42 | Mak This isn't the test that MH referred to because he wouldn't have had it to test yet, but once they've trialled it alongside the other tests to confirm accuracy of greater than 90%, which they're doing, it's a potential game changer for all who want or need a test. Low cost, rapid and available to all, which would be good news for all of us. It isn't connected to a listed company and it's a 'not for profit' concern. There's a market for all tests but best to be aware of competition, which, in my opinion, it would be, rather than being blissfully unaware and in denial. | jev1 | |
02/4/2020 21:16 | Lots of nonsense out there. Let's see how it goes but cheers. | tickboo | |
02/4/2020 21:03 | Tickboo Jocularity aside and as the topic of NCYT has been raised numerous times, I agree that support for Uk innovation has been found wanting along with the government strategy, or lack thereof. Dismal. Herd immunity, nonsense. Cease testing, nonsense. Don't wear masks, nonsense. 60% of deaths would have happened later this year anyway, total guff. Endless. However, I would tread with caution there because of the following, which is another British innovation. £2 for a test and results in five minutes. | jev1 | |
02/4/2020 20:57 | I'm so bad with TR1s! Apologies I have 27,500 here and 18,500 in NCYT. I'll leave my holding here and if NCYT goes big in the next week (could do) I'll sell a fair whack (leave some carry in) and put here. | tickboo | |
02/4/2020 20:48 | Just found myself here and it looks interesting. Is there any evidence that this treatment will help Covid19 other than the implication that it seemed to be beneficial for COPD? Thanks. | glennrcharles | |
02/4/2020 20:46 | Tickboo 'but will get nearer to 50m here than my current 20m' ??? With a holding that size, you'd need to make an offer for SNG. ;o) | jev1 | |
02/4/2020 20:19 | Makendon, best for them to use a watsapp group :) | yet another final | |
02/4/2020 20:12 | So, what do you all think of the MMs having signals? I saw a post on LSE by zebra04 and after looking at the closing bids tonight 16:36 and 18:06 for £5... am now suspicious | makendon | |
02/4/2020 19:53 | Nobby, no reason to doubt it. | rafboy | |
02/4/2020 19:44 | >> rafboy Great info assuming it is true. If they get every centre up and running and they recruit as quickly as Southampton then the trial won't take 2 months! | nobbygnome | |
02/4/2020 19:40 | Yes hope they recover.. Regardless of treatment mode | yet another final | |
02/4/2020 19:29 | What are people's thoughts on 5g and covid 19? | nick9013 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions